|
|
|
| Effect of Diltiazem on blood concentration of Cyclosporine A in renal transplant patients |
| SU Dan1 CHEN Lu2 ZHAGN Lei1 SHEN Aizong1 TANG Liqin1 |
1.Department of Pharmacy, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Anhui Province, Hefei 230001, China;
2.School of Pharmacy, Anhui University of Chinese Medicine, Anhui Province, Hefei 230012, China |
|
|
|
Abstract Objective To explore the clinical effect of combined use of Cyclosporine A (CsA) and Diltiazem (DTZ) in patients undergoing clinical kidney transplantation, and to evaluate the effect of DTZ on the blood concentration of CsA in kidney transplant patients. Methods A total of 108 patients who underwent kidney transplantation at the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) from January 2013 to December 2017 were collected, and they were divided into the control group (54 cases) and the study group (54 cases) by random number table method. The patients in the control group only used CsA after the operation, while the study group received both CsA and DTZ after the operation. The data of CsA dosage and blood drug concentration of two groups one to six months after operation, and the liver and kidney toxicity of CsA were analyzed. Results There were no significant differences in CsA blood concentration and interaction between the two groups after renal transplantation (P ＞ 0.05); the difference was statistically significant in time comparison (P ＜ 0.05). Among them, the CsA blood concentration two to six months after oparation of the two groups were lower than one month after operation, and the CsA blood concentration three to six months after operation were lower than two months after operation, and the differences were statistically significant (P ＜ 0.05). The differences between the two groups in the dose and time of CsA administration were statistically significant (P ＜ 0.05); while the interaction comparison, and the difference was not statistically significant (P ＞ 0.05). Among them, two, four and six months after operation were lower than one month after operation, the dose of CsA used in three months after operation was lower than two months after operation, while four and six months after operation were lower than three months after operation, and the differences were statistical significance (P ＜ 0.05). After treatment, the levels of serum creatinine, urea nitrogen and uric acid between the two groups were lower than those before treatment, and the differences were statistically significant (P ＜ 0.05). Conclusion DTZ can significantly increase the blood concentration of CsA and reduce the dosage of CsA, thereby reducing the side effects of CsA and reducing the economic burden of patients.
|
|
|
|
|
|
[1] Kalim S，Rhee EP. Metabolomics and Kidney Precision Med-icine [J]. Clin J Am Soc Nephrol，2017，12（11）：1726-1727.
[2] 王祥慧.2019 ATC器官移植国际前沿热点及新进展概述[J].器官移植，2020，11（2）：222-233.
[3] Beger RD，Sun J，Schnackenberg LK. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity [J]. Toxicol Appl Pharmacol，2010，243（2）：154-166.
[4] 成晓玲，马洁，陈振萍，等.104例儿童再生障碍性贫血环孢素A浓度监测策略的回顾性分析[J].中国医药导报，2018，15（29）：108-111.
[5] 宋文利，王振.再次肾移植：挑战与机遇并存[J].实用器官移植电子杂志，2019，7（2）：87-89.
[6] Hryniewiecka E，Zegarska J，Zochowska D，et al. Cyclosporine Metabolites′ Metabolic Ratios May Be Markers of Cardiovascular Disease in Kidney Transplant Recipients Treated with Cyclosporine A-Based Immunosuppression Regimens [J]. Cardiovasc Toxicol，2019，19（3）：255-263.
[7] Albitar O，Ballouze R，Harun SN，et al. Population Pharmacokinetic Modeling of Cyclosporine Among Malaysian Renal Transplant Patients：An Evaluation of Methods to Handle Missing Doses in Conventional Drug-Monitoring Data [J]. J Clin Pharmacol，2020，60（11）：1474-1482.
[8] 张文瑞，高媛，卜宁，等.肾移植术后他克莫司与环孢素A治疗有效性和安全性比较的Meta分析[J].中国循证医学杂志，2019，19（9）：1063-1069.
[9] 田普训，敖建华，李宁，等.器官移植免疫抑制剂临床应用技术规范（2019版）[J].器官移植，2019，10（3）：213-226.
[10] 陈泉金，林美钦，廖子彦，等.影响肾移植患者环孢素血药浓度的基因型和群体药动学研究进展[J].解放军药学学报，2017，33（3）：255-258.
[11] Shalaby U. Diltiazem co treatment with cyclosporine for induction of disease remission in sight-threatening non-infectious intraocular inflammation [J]. Jpn J Ophthalmol，2017，61（2）：169-178.
[12] 苏丹，陈露，张蕾，等.环孢素与唑类抗真菌药物相互作用的研究进展[J].广西医学，2020，42（5）：622-624.
[13] 陈鑫，王晓雪，唐坤，等.环孢素A代谢物的研究概况[J].中国医院用药评价与分析，2020，20（3）：372-376.
[14] 周亚男.群体PK方法研究肾移植患者中地尔硫■对他克莫司药动学的影响[D].长沙：中南大学，2013.
[15] Gokce M，Yuzbasioglu MF，Bulbuloglu E，et al. Cilostazol and diltiazem attenuate cyclosporine-induced nephrotoxicity in rats [J]. Transplant Proc，2012，44（6）：1738-1742.
[16] 关玉珍，刘代华.地尔硫■在慢性肾脏病中的应用[J].赣南医学院学报，2018，38（1）：84-87.
[17] Lin Y，Zhang J，Lei W，et al. Diltiazem aggravates testicular function impairment induced by cyclosporine A or tacrolimus in unilateral nephrectomised rats [J]. Andrologia，2019，51（5）：e13251.
[18] 常馨予，郭桂明，刘洋，等.药物相互作用致环孢素不良反应分析及药学监护[J].药学实践杂志，2018，36（4）：365-368.
[19] 李培余.环孢素A治疗药物监测的免疫学方法比较分析[D].天津：天津医科大学，2018.
[20] 王琳珊，邢晓清，刘洪涛，等.环孢素A血药浓度影响因素的研究进展[J].临床合理用药杂志，2019，12（28）：180-181.
[21] 孙搏，郭彦琨，高君伟，等.CYP3A基因多态性与肾移植术后不同时期环孢素浓度剂量个体差异的相关性研究[J].中国药师，2017，20（1）：91-93.
[22] 彭颖，张峻，柳汝明，等.CYP3A5 6986A＞G基因多态性与中国肾移植术后患者环孢素A血药浓度相关性的Meta分析[J].中国药房，2019，30（20）：2855-2861.
[23] Zhou LY，Zuo XC，Chen K，et al. Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients [J]. J Clin Pharm Ther，2016，41（3）：341-347.
[24] 李雨，郭慧蕾，张永.肾病综合征伴急性肾损伤患者地尔硫■合并环孢素的超说明书用药分析[J].中国医院药学杂志，2016，36（5）：407-409.
[25] 桑义民，王淑秋.环孢素A移植肾毒性损害的病理特点及其临床应用探讨[J].中国医学创新，2019，16（20）：71-74.
[26] Starr SP. Immunology Update：Long-Term Care of Solid Organ Transplant Recipients [J]. FP Essent，2016，450：22-27. |
|
|
|
